Abstract. The keratinocyte growth factor receptor (KGFR), also known as FGFR2 IIIb, is mainly localized in epithelial cells and is activated by the keratinocyte growth factor (KGF) that is predominantly synthesized by mesenchymal cells. In this study, we examined the roles of KGFR and KGF in human esophageal cancer (EC). In noncancerous esophageal tissues, KGFR was localized in epithelial cells from the basal region of the epithelium to the lower one-third of the epithelium, and KGF was weakly localized in the basal to parabasal epithelial cells. On the other hand, Ki-67 was localized in the parabasal cells. In EC tissues, KGFR and KGF were expressed in cancer cells in 22 and 37 of 54 patients, respectively. The coexpression of KGFR and KGF in cancer cells was detected in 14 of 54 (26%) patients. Clinicopathologically, KGFR expression correlated with the well-differentiated cell type of EC (p<0.001), and KGF expression correlated with lymphatic invasion and lymph node metastasis (p=0.004 and 0.021, respectively). The coexpression of KGFR and KGF in cancer cells correlated with the well-differentiated cell type of EC (p=0.001). KGFR-positive, KGF-positive and KGFR/KGF coexpression patients tended to have shorter survival rates, but the survival rates were not statistically significantly different (p=0.44, 0.059 and 0.112, respectively). In human EC cell lines (TE-1, TE-8 and TE-11), KGFR mRNA was expressed but no KGF mRNA was detected. The KGFR mRNA level was highest in TE-1 cells, derived from well-differentiated SCC and lowest in TE-8 cells. KGFR was detected in the cancer cell lines by Western blot analysis. Recombinant human KGF significantly stimulated the growth of TE-8 and -11 cells, derived from moderately differentiated SCC, but had no effect on TE-1 cell growth. These results suggest that KGFR expression correlates with the differentiation of a normal esophageal epithelium and the well-differentiated cell type of EC. On the other hand, KGF may induce the growth of some EC cells in a paracrine manner and closely correlates with lymphatic invasion and lymph node metastasis.
Introduction
The fibroblast growth factor (FGF) family has at least 22 members, which range in molecular mass from 17 to 34 kD and share 13-71% amino acid identities (1, 2) . FGFs have been implicated in the regulation of cell differentiation, proliferation, migration and survival in many different cell types. The biological activities of FGFs are mediated by FGF receptors (FGFRs) that undergo dimerization and autophosphorylation after ligand binding. FGFRs are encoded by four distinct genes (designated Fgfr1, 2, 3 and 4) characterized by two or three extracellular immunoglobulin (Ig)-like loops, a single transmembrane region and a cytoplasmic tyrosine kinase domain. The third Ig-like loop is encoded by two or three exons of Fgfr1, 2 and 3, enabling the synthesis of alternatively spliced isoforms (3, 4) . The two different receptor isoforms of Fgfr2 are designated FGFR2 IIIb, also known as the keratinocyte growth factor receptor (KGFR), and FGFR2 IIIc. KGFR is specifically localized in epithelial cells whose growth is induced by FGF-1, FGF-3, the keratinocyte growth factor (KGF/FGF-7) or FGF-10 (KGF-2), whereas FGFR2 IIIc binds FGF-1, -2, -4, -6 and -9 and is expressed mainly in mesenchymal cells (4, 5) .
Mice null for the Fgfr2 IIIb isoform but still retaining Fgfr2 IIIc exhibit dysgenesis of the kidneys, salivary glands, adrenal glands, thymus, pancreas, skin, otic vesicles, glandular stomach and hair follicles, and agenesis of the lungs, anterior pituitary gland, thyroid gland, teeth and limbs (6) (7) (8) . KGFR is expressed in epithelial cells throughout the gastrointestinal (GI) tract, and an intraperitoneal injection of KGF enhances normal intestinal epithelial cell growth (9, 10) . In the early stage of esophageal ulcer healing, the expression levels of Expression and roles of keratinocyte growth factor and its receptor in esophageal cancer cells (12) (13) (14) . Pancreatic cancer cell line growth is stimulated by rhKGF administration (15) . Furthermore, a dose-dependent cell growth stimulated by KGF has been observed in well-differentiated colorectal cancer cell lines (16) . KGF enhances the proliferation of gastric carcinoma cells derived from scirrhous tumors (17) . In esophageal cancer (EC), 13 of the EC cell lines express KGFR mRNA (18) . These lines of evidence suggest that the KGF-KGFR pathway plays an important role in the growth of epithelial cells in the GI tract, as well as cancer cells.
On the other hand, the growth of most human cancer cell lines (30/35) is not significantly affected by rhKGF (19) . KGF fails to effectively stimulate the growth of two of three pancreatic cancer cell lines and of colorectal cancer cell lines, established from undifferentiated cancer or from a metastatic nodule (13, 15) . KGF-transfected prostate epithelial cells are not tumorigenic in nude mice (20) . A stable transfectant of Kgfr of salivary adenocarcinoma cells induces cancer cell differentiation and apoptosis (21) .
Recently, the U.S. Food and Drug Administration (FDA) has approved the truncated form of recombinant KGFpalifermin for clinical use for patients with hematologic malignancies. The use of palifermin in patients with hematologic malignancies reduces the incidence and duration of severe oral mucositis after intensive chemoradiotherapy (22) . The safety and efficacy of palifermin in nonhematologic malignancies including EC have not yet been established; hematologic malignancies do not have KGFR, but most cancer cells do (23) . In a randomized phase II clinical trial in patients with advanced colorectal cancer who were treated with 5-FU and leucovorin, patients who received palifermin had a lower incidence of ulcerative oral mucositis than those who did not receive palifermin (24) .
In this study, we examined the expression and roles of KGFR and KGF in EC cells. We report that KGFR expression and the coexpression of KGFR and KGF in cancer cells correlate with the differentiated type of EC, and that KGF expression in cancer cells correlates with lymphatic invasion and lymph node metastasis. The KGFR-positive, KGF-positive and KGFR/KGF coexpression patients tend to have shorter survival rates than KGFR-, KGF-and KGFR/KGF-negative patients, respectively. Furthermore, exogenous KGF induces the growth of some EC cells in a paracrine manner. Human EC cell lines. TE-1, TE-8 and TE-11 EC cell lines were obtained from the Cell Resource Center for Biomedical Research, Institute of Development, Aging and Cancer, Tohoku University (Sendai, Japan). TE-1 cells were established from well-differentiated SCC, and TE-8 and TE-11 cells were established from moderately differentiated SCC. The cells were grown in RPMI-1640 medium containing 10% heatinactivated fetal bovine serum (FBS), 100 U/ml penicillin, 100 μg/ml streptomycin and 0.25 μg/ml amphotericin B at 37˚C in a humidified 5% CO 2 atmosphere.
Materials and methods

Materials
Immunohistochemistry. The anti-KGFR antibody used was an affinity-purified rabbit polyclonal antibody raised against a peptide corresponding to amino acids of human KGFR, as previously reported (25) . Paraffin-embedded sections (3 μm thick) were subjected to immunostaining using a Histofine Simple Stain Max PO (R) or (G) kit. After deparaffinization, the endogenous peroxidase activity was blocked by incubation in 0.3% hydrogen peroxide in methanol for 30 min. The tissue sections were incubated with the appropriate antibody for 16 h at 4˚C (1:1000 dilution for the anti-KGFR antibody, 1:100 dilution for the anti-KGF antibody) using phosphate-buffered saline (PBS) containing 1% bovine serum albumin (BSA). The bound antibodies were detected with the Simple Stain Max PO (G) or (R) reagent using diaminobenzidine tetrahydrochloride (DAB) as the substrate. The sections were counterstained Table I . Correlation of clinicopathological features and KGFR, KGF or coexpression of KGFR and KGF in esophageal cancers. 
with Mayer's hematoxylin. For Ki-67 immunostaining, the tissue sections were preheated in 10 mM citrate buffer (pH 6.0) for 15 min at 121˚C in an autoclave oven. Then, endogenous peroxidase activity was blocked by incubation in 0.3% hydrogen peroxide in methanol for 30 min. The tissue sections were incubated with anti-Ki-67 (dilution, 1:100) antibody in PBS containing 1% BSA for 16 h at 4˚C. The bound antibodies were detected using the Simple Stain Max PO (M) reagent with DAB as the substrate. The sections were lightly counterstained with Mayer's hematoxylin. Positivity for KGFR and KGF was classified according to the percentage of positive tumor cells regardless of staining intensities: when KGFR staining was observed in the cytoplasm or membrane of >10% of the tumor cells, the patients were designated KGFR-positive (26, 27) ; when KGF staining was observed in the cytoplasm of >30% of the tumor cells, the patients were designated KGF-positive (28) . Two investigators (M.Y. and T.I.) separately evaluated all the specimens in a blind manner.
Reverse transcription polymerase chain reaction (RT-PCR).
Total RNA was extracted using an RNeasy mini kit according to the protocol of the manufacturer. Then, cDNA synthesis and RT-PCR were performed using the Takara RNA PCR kit. The primer pair used for KGFR cDNA preparation was derived from sequences of human KGFR cDNA, corresponding to nucleotides (nts) 1580-1603 (5'-TCT-CAA-GCA-CTC-GGG-GAT-AAA-TAG-3') and 1839-1859 (5'-CGT-GTT-CTT-CAT-TCG-GCA-CAG-3') (280 bp, accession no. NM_022970). The primers used for KGF corresponded to nts 411-430 (5'-ATG-TTA-TTC-ATG-AAC-ACC-CG-3') and 1046-1065 (5'-CTG-CTG-GAA-CTG-GGT-TCT-TT-3') of the human KGF cDNA (655 bp, NM_002009). ß-actin mRNA, as the positive control, was amplified using the following primer pairs: nts 331-353 (5'-GCA-CCA-CAC-CTT-CTA-CAA-TGA-GC-3') and 472-493 (5'-TAG-CAC-AGC-CTG-GAT-AGC-AAC-G-3') (163 bp, accession no. NM_001101). PCR was carried out in a Takara PCR thermal cycler MP (Takara) for 2 min at 94˚C and then for 35 cycles, each consisting of 30 sec at 94˚C, 30 sec at 60˚C and 1 min at 72˚C. Before cDNA synthesis, total RNA was run on a denatured gel to eliminate the possibility of RNA degradation during the extraction steps, and then used for transcription. As a negative control, RNA without RT was used as the template for PCR.
Quantitative RT-PCR. One microgram of total RNA sample was used for RT with the transcriptor first-strand cDNA synthesis kit following the manufacturer's protocol. Quantitative RT-PCR (qRT-PCR) was performed using a LightCyclerFastStartDNA Master SYBR-Green I system. The primer pairs used for KGFR and ß-actin were the same as those employed in RT-PCR. Twenty microliters of the PCR mixture containing 2 μl of template cDNA, 3 mM MgCl 2 , 0.5 μM of each primer and LightCycler-FastStartDNA Master SYBR-Green I mix was loaded to the capillary tube. qRT-PCR was carried out in a LightCycler, and the PCR products were analyzed using LightCycler Data Analysis software Ver. 3.5 (Roche Diagnostics GmbH). To confirm amplification specificity, the PCR products were used for melting curve analysis. Results were expressed as KGFR/ß-actin, an internal standard concentration ratio. The optimized program involved denaturation at 95˚C for 10 min, followed by 45 cycles of amplification (at 95˚C for 10 sec, 58˚C for 10 sec, and 72˚C for 12 sec) for KGFR, and by 40 cycles of amplification (at 95˚C for 10 sec, 64˚C for 10 sec, and 72˚C for 7 sec) for ß-actin.
Western blot analysis. The same anti-KGFR antibody used for immunohistochemical analysis was utilized for Western blot analysis. Protein extraction was performed using the M-PER (mammalian protein extraction reagent), according to the manufacturer's protocol. Proteins from the EC cell lines were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) under the reducing condition, and the separated proteins were transferred onto Immobilon PVDF transfer membranes. The membranes were preincubated with 5% skim milk/TBS-T for 2 h and then incubated for 16 h with the anti-KGFR antibody (dilution, 1:2000). The membranes were sequentially washed and incubated with the secondary HRP-conjugated anti-rabbit IgG antibody for 60 min. After washing, the blots were visualized by enhanced chemiluminescence and detected using the ChemiDoc XRS system (Bio-Rad Laboratories, Inc., Hercules, CA, USA). To confirm almost equal loads of the proteins, the membrane was washed and reprobed with the anti-ß-actin antibody.
Effects of rhKGF on EC cell growth. TE-1, TE-8 and TE-11
EC cells were plated on a 96-well plate at a density of 2x10 3 cells/well and cultured for 24 h in RPMI-1640 medium containing 10% FBS. These cells were then cultured in the same medium, with 0, 1, 10 and 100 ng/ml rhKGF for 48 h. The growth rates of the cells were evaluated using cell counting kit-8.
Statistical analysis.
To analyze the correlation between KGFR expression and clinicopathological features, the χ 2 test or Mann-Whitney U test was used. Group comparisons were analyzed by one-way analysis of variance (ANOVA). The Tukey-Kramer test was used to compare the expression level of KGFR mRNA in EC cell lines and the Dunnett test was used to assess the effect of rhKGF on EC cell growth (Statview version 4.5). The mean ± standard error (SE) of two separate experiments was evaluated. P<0.05 was considered statistically significant.
Results
Immunohistochemical analysis of KGFR and KGF in EC.
To confirm the localization of KGFR in human EC tissues, immunohistochemical staining was performed. In noncancerous esophageal tissues, KGFR was localized in the basal region to the lower one-third of squamous epithelial cells (Fig. 1A) . KGF was weakly localized in the basal region to the parabasal region of the squamous epithelium (Fig. 1B) . Ki-67 was localized in the parabasal region of the squamous epithelium (Fig. 1C) . In EC tissues, KGFR was expressed in the cell membrane or cytoplasm of cancer cells adjacent to keratinizing lesions or large squamous pearls ( Fig. 2A) . KGF was expressed in the cytoplasm of cancer cells (Fig. 2B) . KGFR and KGF expression in 22 and 37 of the 54 (41 and 69%, respectively) patients was detected in cancer cells, and the coexpression of KGFR and KGF in the cancer cells was detected in 14 of the 54 (26%) EC patients. Clinicopathologically, KGFR expression significantly correlated with well-differentiated cell types, but not with other factors (p<0.001, Table I ). KGF expression significantly correlated with lymphatic invasion and lymph node metastasis (p=0.004 and 0.021, respectively, Table I ). The coexpression of KGFR and KGF correlated with welldifferentiated cell types (p<0.001).
Kaplan-Meier survival curve. The KGFR-positive, KGFpositive and KGFR/KGF coexpression patients tended to have shorter survival rates than the KGFR-, KGF-and KGFR/KGFnegative patients, but the survival rates were not statistically significantly different (Fig. 3A-C: p=0 .44, 0.059 and 0.112, respectively).
RT-PCR of KGFR and KGF in EC cell lines.
To examine the expression of KGFR and KGF in EC cell lines, RT-PCR analysis was performed. KGFR mRNA was detected in the TE-1, TE-8 and TE-11 cells (Fig. 4, upper panel) , but no KGF mRNA was detected in any of the tested cancer cell lines (Fig. 4, middle panel) . ß-actin mRNA was detected in all of the cancer cell lines tested (Fig. 4, lower panel) .
Quantitative RT-PCR of KGFR in EC cell lines.
To measure the expression level of KGFR mRNA in EC cell lines, qRT-PCR analysis was performed. The KGFR mRNA expression level was highest in the TE-1 cells and lowest in the TE-8 cells (p<0.05, Fig. 5 ). The KGFR mRNA expression level in the TE-1 cells was 6.4-fold higher than that in the TE-8 cells.
Western blot analysis of KGFR in EC cell lines.
To characterize KGFR protein expression in EC cell lines, total protein was extracted from the TE-1, TE-8 and TE-11 cells. The Western blot analysis of these cell lines using the anti-KGFR antibody showed a single 105-kD band corresponding to KGFR (Fig. 6,  upper panel) . A 42-kD band corresponding to ß-actin was detected at almost the same intensities in all of the cancer cell lines (Fig. 6, lower panel) .
Effect of rhKGF on EC cell growth. To determine whether KGF stimulates EC cell growth, rhKGF was added to the TE-1, Figure 1 . Immunohistochemical examination of KGFR, KGF and Ki-67 in noncancerous esophageal tissues. KGFR was localized in the basal region of the epithelium to the lower one-third of normal squamous epithelial cells (A). KGF was faintly localized in the basal region to the parabasal region (B). Ki-67 was localized in the parabasal region (C). Original magnification: x400. TE-8 and TE-11 cells. TE-1 did not proliferate with the addition of 10 or 100 ng/ml rhKGF (Fig. 7A, p=0 .131 and 0.083, respectively). However, the growth rate of the TE-8 cells increased with the addition of 10 and 100 ng/ml KGF at 48 h, as compared with the nontreated controls (Fig. 7B,  p=0 .008 and 0.001, respectively). The growth rates of TE-11 cells increased with the addition of 10 and 100 ng/ml rhKGF (Fig. 7C, p=0 .068 and 0.019, respectively).
Discussion
KGFR is localized in normal epithelial cells in the GI tract (9) . In this study, we found that, in noncancerous esophageal tissues, KGFR is localized in the lower one-third of squamous epithelial cells and its localization is broader than that of Ki-67, a proliferating cell marker. In gastric and colorectal tissues, KGFR is localized in the luminal surface of epithelial cells, but Ki-67 is localized in the nuclei of ductal cells in the basal and parabasal regions (14, 27) . These findings suggest that KGFR plays important roles not only in epithelial cell proliferation in the GI tract, but also in cell differentiation. Histologically, most ECs are classified as SCC. In SCC, KGFR was expressed in uterine cervical cancer cell lines (26) . KGFR-expressing uterine cervical cancer cells had a large pleomorphic cytoplasm and are histologically similar to welldifferentiated SCC cells. Uterine cervical cancer cells showing a round or oval cytoplasm and a high nuclear/cytoplasm ratio as poorly differentiated SCC cells did not express KGFR. Previously, KGFR mRNA expression was reported to have been detected in 13 EC cell lines, but no KGF mRNA was present in the cells (18) . Our results of KGFR and KGF mRNA expression in EC cells were identical with this report. All three EC cell lines that expressed KGFR originated from welldifferentiated or moderately differentiated SCC cells. qRT-PCR analysis showed that KGFR mRNA is more strongly expressed in the TE-1 cells from well-differentiated SCC cells than in the TE-8 or TE-11 cells from moderately differentiated SCCs. These lines of evidence suggest that the KGFR expression level in cancer cells correlates with the well-differentiated type of SCC cells.
We previously reported the KGFR expression in cancer cell lines derived from the GI tract, including the esophagus, stomach and colon (14, 27) . Conventional gastric cancer cell lines expressed KGFR, but special types of gastric cancer cell line from metastatic foci of adenosquamous cells and α-fetoprotein-producing gastric cancer cells did not express KGFR (27, 29) . In colorectal cancer cell lines, KGFR was strongly expressed in cancer cells originating from welldifferentiated adenocarcinoma (14) . In human breast adenocarcinoma cell lines, the KGFR expression level in welldifferentiated (estrogen receptor, ER-positive) cancer cell lines was markedly higher than in the poorly differentiated (ER-negative) cancer cell lines (30) . KGFR, which is almost identical in molecular weight to KGFR in human colorectal cancer cell lines was detected in EC cell lines. To our knowledge, this is the first report on KGFR expression in EC cell lines at the protein level.
A previous report showed that KGF enhances DNA synthesis and induces TE-1 cell growth (18) . In this study, KGF did not induce TE-1 cell growth, but induced TE-8 and TE-11 cell growth in a dose-dependent manner. The different responses of the TE-1 cells to KGF administration may depend on FBS concentration. We used 10% FBS in our culture medium, but previous researchers used a lower serum concentration of 0.01% or 0.7%. A higher FBS concentration contains many kinds of growth factors at high concentrations; thus, FBS may abolish the growth stimulatory effect of exogenous KGF in EC. Furthermore, the growth induction of KGF in the TE-8 and TE-11 cells at high FBS concentration suggests the high effectiveness of KGF on these cells. All these cells possess KGFR, but TE-1 cells have the highest KGFR expression level. Growth induction by rhKGF in SCC cells may not be dependent on KGFR mRNA expression level. Alternatively, a high KGFR expression level may have different effects, including those on TE-1 cell differentiation. KGF is reported to induce the growth of well-differentiated colorectal cells, but does not stimulate the growth of undifferentiated cancer cells (13, 16) . The TE-1 cells were from well-differentiated SCC cells, and the TE-8 and TE-11 cells were from moderately differentiated SCC cells. The reason for the different responses of these cells is not yet known; however, the role of KGF may differ between SCC and adenocarcinoma. Further study of the growth stimulatory effect of KGF on various histological types of cancer cell seems necessary.
Recently, we have found that KGF expression in pancreatic cancer cells correlates with venous invasion (28) . In this study, exogenous KGF induced EC cell growth. Furthermore, KGF expression in EC cells correlates with lymphatic invasion and lymph node metastasis. EC cells whose growth has been induced by KGF may easily invade lymphatic vessels in the submucosa and lead to regional lymph node metastasis.
In summary, we found that KGFR is localized in a noncancerous esophageal epithelium, and that KGFR expression Figure 7 . Effect of rhKGF on esophageal cancer cell growth. TE-1 growth was not significantly stimulated with the addition of 10 and 100 ng/ml rhKGF (A). In contrast, TE-8 and TE-11 cell growth rates increased after the addition of 10 and 100 ng/ ml rhKGF at 48 h (B and C). * p<0.05, ** p<0.01, *** p<0.001; NS, not significant. in EC correlates with highly differentiated histological type. Moreover, KGF has a potential to stimulate the growth of some EC cells and its expression correlates with lymphatic invasion and lymph node metastasis.
